Product Description
Recombinant human neuregulin-1 (Neucardin®), developed by Zensun, is a novel genetically engineered biologic used in the treatment of mild and moderate chronic heart failure (CHF). The advantage of Neucardin® is that it can specifically target the cardiac muscle cell, repair the cell structure and improve function during heart contraction and relaxation, thereby improving cardiac function and reversing pathological ventricular remodeling,and significantly reducing death rate and readmission rate while improving the quality of life. (Sourced from: http://www.zensunus.com/product/center?id=19)
Mechanisms of Action: ERBB2 Binder
Novel Mechanism: Yes
Modality: Coagulation Factor
Route of Administration: Subcutaneous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Zensun
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 2
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Heart Failure, Chronic|Heart Failure, Systolic|Heart Murmurs|Systolic Murmurs
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| ZS-01-306 | P3 |
Recruiting |
Heart Failure, Chronic |
2026-02-01 |
38% |
2024-02-02 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
| ZS-01-308B | P3 |
Completed |
Heart Failure, Chronic|Heart Murmurs|Heart Failure, Systolic|Systolic Murmurs |
2024-08-30 |
38% |
2025-01-29 |